Vaxcyte names new chief medical and legal officers, moves up OPUS-1 data timing
Luis Jodar joins as CMO and David McAvoy as CLO as Vaxcyte says VAX-31 Phase 3 topline data will arrive by end of October 2026 instead of the fourth quarter.
SEC filing
Latest
3 stories
Thursday, September 3
Wednesday, August 5
Vaxcyte reports Q2 2026 results, OPUS Phase 3 trials fully enrolled, initiates VAX-A1 Phase 1
OPUS-1 topline data are expected in Q4 2026, with OPUS-2, OPUS-3 and VAX-31 infant data to follow in the first half of 2027, alongside a new VAX-A1 Phase 1 start.
SEC filing
Wednesday, July 15
Vaxcyte board sees director change as Lukatch retires, Markels joins
Heath Lukatch is retiring from Vaxcyte's board effective July 16, 2026, while John Markels joins the same day as a Class II director.
SEC filing